Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CRISPR Therapeutics AGCRSP · Entity 3852 | CBO & COO | August 16, 2022 | August 18, 2022 |
| Dyne Therapeutics, Inc.DYN · Entity 3948 | Director | July 05, 2022 | July 06, 2022 |
| Jade Biosciences, Inc.JBIO · Entity 4757 | Director | June 09, 2026 | June 11, 2026 |
| Jasper Therapeutics, Inc.JSPR · Entity 7588 | Director | June 07, 2023 | June 08, 2023 |
| Oruka Therapeutics, Inc.ORKA · Entity 3781 | Director · Chief Executive Officer | October 01, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CRISPR Therapeutics AG
Report date August 16, 2022 · Filed August 18, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 12,500 |
Reported balance
After 2022-08-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-08-16 · Grant · Acquired 12,500 · Balance 12,500 F1: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F2: The restricted stock units shall vest in full on August 16, 2023, subject to continued service to the Company or any of its subsidiaries. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F2: The restricted stock units shall vest in full on August 16, 2023, subject to continued service to the Company or any of its subsidiaries.
Dyne Therapeutics, Inc.
Report date July 05, 2022 · Filed July 06, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.54 · Expires 2030-07-30 | Direct | 7,222 |
Reported balance
After 2022-07-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-07-05 · Grant · Acquired 7,222 · Balance 7,222 F1: The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an Investigational New Drug (IND) application submitted to the U.S. Food and Drug Administration (FDA) by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an Investigational New Drug (IND) application submitted to the U.S. Food and Drug Administration (FDA) by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved.
Jade Biosciences, Inc.
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.22 · Expires 2036-06-08 | Direct | 34,843 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 34,843 · Balance 34,843 F1: This option represents a right to purchase shares of the Issuer's common stock, which vests in full on the earlier of (i) June 9, 2027 or (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continued service to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: This option represents a right to purchase shares of the Issuer's common stock, which vests in full on the earlier of (i) June 9, 2027 or (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continued service to the Issuer.
Jasper Therapeutics, Inc.
Report date June 07, 2023 · Filed June 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.60 · Expires 2033-06-07 | Direct | 47,000 |
Reported balance
After 2023-06-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-07 · Grant · Acquired 47,000 · Balance 47,000 |
Oruka Therapeutics, Inc.
Report date October 01, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 923,128 |
Ending reported balance
After 2026-10-01 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-10-01 · Exercise / conversion · Acquired 25,000 · Balance 948,128 Row 2 · 2026-10-01 · Sale · Disposed 16,246 · Balance 931,882 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.75 to $83.73, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. Row 3 · 2026-10-01 · Sale · Disposed 8,554 · Balance 923,328 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.75 to $84.69, inclusive. Row 4 · 2026-10-01 · Sale · Disposed 200 · Balance 923,128 F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.75 to $84.81, inclusive. |
| Employee Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.80 · Expires 2034-07-14 | Direct | 1,528,513 |
Reported balance
After 2026-10-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-10-01 · Exercise / conversion · Disposed 25,000 · Balance 1,528,513 F5: The warrant vests as to 1/4 of the underlying shares on April 3, 2025 and as to 1/48 of the underlying shares monthly from April 3, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.75 to $83.73, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.75 to $84.69, inclusive.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.75 to $84.81, inclusive.
F5: The warrant vests as to 1/4 of the underlying shares on April 3, 2025 and as to 1/48 of the underlying shares monthly from April 3, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 23, 2021 Filed Mar 25, 2021 21:39 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 20,000 | $40.87 | $817,400.00 |
DisclosureSEC source: 0001209191-21-023069 · doc4.xml · nonDerivative · entry 4 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 21:39 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 10,000 | $29.87 | $298,700.00 |
DisclosureSEC source: 0001209191-21-023069 · doc4.xml · nonDerivative · entry 3 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 21:39 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 22,000 | $51.49 | $1,132,780.00 |
DisclosureSEC source: 0001209191-21-023069 · doc4.xml · nonDerivative · entry 2 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 23, 2021 Filed Mar 25, 2021 21:39 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 12,000 | $44.67 | $536,040.00 |
DisclosureSEC source: 0001209191-21-023069 · doc4.xml · nonDerivative · entry 1 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 11, 2021 Filed Mar 12, 2021 22:47 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantRestricted Stock Units · Derivative | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-020257 · doc4.xml · derivative · entry 4 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Shares · 12,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F5 · derivative.exercise_date: This restricted stock unit award was granted on March 11, 2021 with respect to 12,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024 and (iv) one quarter of the shares vesting on March 11, 2025. F5 · derivative.expiration_date: This restricted stock unit award was granted on March 11, 2021 with respect to 12,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024 and (iv) one quarter of the shares vesting on March 11, 2025. Read SEC document |
| March 11, 2021 Filed Mar 12, 2021 22:47 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 33,334 | $0.00 Strike: $133.88 | $0.00 |
DisclosureSEC source: 0001209191-21-020257 · doc4.xml · derivative · entry 3 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,334 Underlying: Common Shares · 33,334 shares Expires 2031-03-11 F4 · derivative.exercise_date: This option was granted on March 11, 2021 with respect to 33,334 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 11, 2021. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 22:47 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Tax withholdingCommon Shares | 2,141 | $124.15 | $265,805.15 |
DisclosureSEC source: 0001209191-21-020257 · doc4.xml · nonDerivative · entry 2 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,050 F3 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 22:47 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 4,583 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-020257 · doc4.xml · nonDerivative · entry 1 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,191 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This restricted stock unit award was granted on March 10, 2020 with respect to 13,750 Common Shares, with (i) one third of the shares vesting on March 10, 2021, (ii) one third of the shares vesting on March 10, 2022, and (iii) one third of the shares vesting on March 10, 2023. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 23:07 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,334 | $0.00 Strike: $14.43 | $0.00 |
DisclosureSEC source: 0001209191-21-004458 · doc4.xml · derivative · entry 17 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,666 Underlying: Common Shares · 16,334 shares Expires 2027-06-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F16 · derivative.exercise_date: 100% of the shares shall vest in 48 equal monthly installments on the fifteenth day of each month, with the first vesting event on July 15, 2017. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 23:07 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,666 | $0.00 Strike: $12.57 | $0.00 |
DisclosureSEC source: 0001209191-21-004458 · doc4.xml · derivative · entry 16 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 8,666 shares Expires 2026-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F15 · derivative.exercise_date: 100% of the shares shall vest in 48 equal monthly installments on the thirty-first day of each month, with the first vesting event on October 31, 2016. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 23:07 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 2 | $219.99 | $439.98 |
DisclosureSEC source: 0001209191-21-004458 · doc4.xml · nonDerivative · entry 15 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F14 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $219.99 to $219.99, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 23:07 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 701 | $218.54 | $153,196.54 |
DisclosureSEC source: 0001209191-21-004458 · doc4.xml · nonDerivative · entry 14 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,002 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.25 to $218.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 23:07 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 9,997 | $217.42 | $2,173,547.74 |
DisclosureSEC source: 0001209191-21-004458 · doc4.xml · nonDerivative · entry 13 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,703 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $217.22 to $217.93, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 23:07 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 1,500 | $216.39 | $324,585.00 |
DisclosureSEC source: 0001209191-21-004458 · doc4.xml · nonDerivative · entry 12 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $216.00 to $216.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 23:07 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 700 | $214.60 | $150,220.00 |
DisclosureSEC source: 0001209191-21-004458 · doc4.xml · nonDerivative · entry 11 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,200 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $214.60 to $214.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 23:07 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 2,800 | $213.64 | $598,192.00 |
DisclosureSEC source: 0001209191-21-004458 · doc4.xml · nonDerivative · entry 10 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,900 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $213.48 to $214.31, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 23:07 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 634 | $212.20 | $134,534.80 |
DisclosureSEC source: 0001209191-21-004458 · doc4.xml · nonDerivative · entry 9 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $212.01 to $212.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 23:07 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 16,344 | $14.43 | $235,843.92 |
DisclosureSEC source: 0001209191-21-004458 · doc4.xml · nonDerivative · entry 8 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,334 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 23:07 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 200 | $217.45 | $43,490.00 |
DisclosureSEC source: 0001209191-21-004458 · doc4.xml · nonDerivative · entry 7 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $217.42 to $217.47, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 23:07 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 400 | $216.24 | $86,496.00 |
DisclosureSEC source: 0001209191-21-004458 · doc4.xml · nonDerivative · entry 6 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,200 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $216.15 to $216.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 23:07 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 1,400 | $214.46 | $300,244.00 |
DisclosureSEC source: 0001209191-21-004458 · doc4.xml · nonDerivative · entry 5 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,600 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $214.125 to $214.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 23:07 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 1,200 | $213.71 | $256,452.00 |
DisclosureSEC source: 0001209191-21-004458 · doc4.xml · nonDerivative · entry 4 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $213.10 to $214.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 23:07 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 2,555 | $212.54 | $543,039.70 |
DisclosureSEC source: 0001209191-21-004458 · doc4.xml · nonDerivative · entry 3 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,200 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $212.01 to $212.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 23:07 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 2,911 | $211.44 | $615,501.84 |
DisclosureSEC source: 0001209191-21-004458 · doc4.xml · nonDerivative · entry 2 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,755 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $211.01 to $212.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 15, 2021 Filed Jan 20, 2021 23:07 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 8,666 | $12.57 | $108,931.62 |
DisclosureSEC source: 0001209191-21-004458 · doc4.xml · nonDerivative · entry 1 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 15, 2021 Filed Mar 12, 2021 22:37 UTC Amendment | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 16,334 | $14.43 | $235,699.62 |
DisclosureSEC source: 0001209191-21-020248 · doc4a.xml · nonDerivative · entry 1 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,942 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This amended Form 4 is being filed to correct the number of shares acquired on January 15, 2021. Read SEC document |
| January 02, 2021 Filed Jan 4, 2021 21:12 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Tax withholdingCommon Shares | 9,392 | $153.11 | $1,438,009.12 |
DisclosureSEC source: 0001209191-21-000256 · doc4.xml · nonDerivative · entry 1 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,608 F1 · kind: On January 2, 2019, the reporting person was granted 20,000 restricted stock units. The restricted stock units vested in full on January 2, 2021. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| October 05, 2020 Filed Oct 6, 2020 21:38 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 16,666 | $0.00 Strike: $86.75 | $0.00 |
DisclosureSEC source: 0001209191-20-054066 · doc4.xml · derivative · entry 1 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,666 Underlying: Common Shares · 16,666 shares Expires 2030-10-05 F1 · derivative.exercise_date: This option was granted on October 05, 2020 with respect to 16,666 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 05, 2020. Read SEC document |
| September 21, 2020 Filed Sep 23, 2020 23:04 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | ConversionSeries B Preferred Stock · Derivative | 35,574 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-026183 · doc4.xml · derivative · entry 5 Klein Lawrence Otto · CIK 0001762583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,725 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. Read SEC document |
| September 21, 2020 Filed Sep 23, 2020 23:04 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | ConversionCommon Stock | 10,725 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-026183 · doc4.xml · nonDerivative · entry 1 Klein Lawrence Otto · CIK 0001762583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,725 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. Read SEC document |
| August 07, 2020 Filed Sep 23, 2020 23:04 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | PurchaseSeries B Preferred Stock · Derivative | 35,574 | $2.81 | $99,998.51 |
DisclosureSEC source: 0000899243-20-026183 · doc4.xml · derivative · entry 4 Klein Lawrence Otto · CIK 0001762583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,574 Underlying: Common Stock · 10,725 shares Expires not disclosed F4 · derivative.exercise_price: The Series B Preferred Stock was convertible into common stock on a 3.3169-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F4 · derivative.exercise_date: The Series B Preferred Stock was convertible into common stock on a 3.3169-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F4 · derivative.expiration_date: The Series B Preferred Stock was convertible into common stock on a 3.3169-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. Read SEC document |
| July 31, 2020 Filed Sep 23, 2020 23:04 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock Option (right to buy) · Derivative | 14,444 | $0.00 Strike: $5.54 | $0.00 |
DisclosureSEC source: 0000899243-20-026183 · doc4.xml · derivative · entry 3 Klein Lawrence Otto · CIK 0001762583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,444 Underlying: Common Stock · 14,444 shares Expires 2030-07-30 F3 · derivative.exercise_date: The option was granted on July 31, 2020. The shares underlying the option are scheduled to vest over four years in equal quarterly installments through July 31, 2024. Read SEC document |
| July 31, 2020 Filed Sep 23, 2020 23:04 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock Option (right to buy) · Derivative | 11,156 | $0.00 Strike: $5.54 | $0.00 |
DisclosureSEC source: 0000899243-20-026183 · doc4.xml · derivative · entry 2 Klein Lawrence Otto · CIK 0001762583 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,156 Underlying: Common Stock · 11,156 shares Expires 2030-07-30 F2 · derivative.exercise_date: The option was granted on July 31, 2020. The shares underlying the option are scheduled to vest over four years in equal quarterly installments through July 31, 2024. Read SEC document |
| June 25, 2020 Filed Jun 26, 2020 20:33 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,912 | $0.00 Strike: $12.57 | $0.00 |
DisclosureSEC source: 0001209191-20-039086 · doc4.xml · derivative · entry 14 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,666 Underlying: Common Shares · 4,912 shares Expires 2026-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: 100% of the shares shall vest in 48 equal monthly installments on the thirty-first day of each month, with the first vesting event on October 31, 2016. Read SEC document |
| June 25, 2020 Filed Jun 26, 2020 20:33 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 4,912 | $75.18 | $369,272.37 |
DisclosureSEC source: 0001209191-20-039086 · doc4.xml · nonDerivative · entry 11 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.6850, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 25, 2020 Filed Jun 26, 2020 20:33 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 4,912 | $12.57 | $61,743.84 |
DisclosureSEC source: 0001209191-20-039086 · doc4.xml · nonDerivative · entry 10 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,912 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 24, 2020 Filed Jun 26, 2020 20:33 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (Right to Buy) · Derivative | 26,422 | $0.00 Strike: $12.57 | $0.00 |
DisclosureSEC source: 0001209191-20-039086 · doc4.xml · derivative · entry 13 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,578 Underlying: Common Shares · 26,422 shares Expires 2026-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: 100% of the shares shall vest in 48 equal monthly installments on the thirty-first day of each month, with the first vesting event on October 31, 2016. Read SEC document |
| June 24, 2020 Filed Jun 26, 2020 20:33 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (Right to Buy) · Derivative | 38,666 | $0.00 Strike: $5.86 | $0.00 |
DisclosureSEC source: 0001209191-20-039086 · doc4.xml · derivative · entry 12 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 38,666 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The Reporting Person was granted an option to purchase 106,666 shares on March 2, 2016. 43,000 of such options were previously exercised, and the shares underlying those options were sold. 25% of this option became vested and fully exercisable on February 1, 2017, and the remaining 75% of the shares shall vest in 36 equal monthly installments on the first day of each month thereafter. Read SEC document |
| June 24, 2020 Filed Jun 26, 2020 20:33 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 2,913 | $76.26 | $222,138.10 |
DisclosureSEC source: 0001209191-20-039086 · doc4.xml · nonDerivative · entry 9 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.03 to $76.62, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 24, 2020 Filed Jun 26, 2020 20:33 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 12,175 | $75.32 | $917,053.87 |
DisclosureSEC source: 0001209191-20-039086 · doc4.xml · nonDerivative · entry 8 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,913 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.95, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 24, 2020 Filed Jun 26, 2020 20:33 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 800 | $76.50 | $61,200.96 |
DisclosureSEC source: 0001209191-20-039086 · doc4.xml · nonDerivative · entry 7 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,088 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.45 to $76.62, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 24, 2020 Filed Jun 26, 2020 20:33 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 3,934 | $75.94 | $298,736.16 |
DisclosureSEC source: 0001209191-20-039086 · doc4.xml · nonDerivative · entry 6 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,888 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.40 to $76.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 24, 2020 Filed Jun 26, 2020 20:33 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 6,600 | $74.90 | $494,322.84 |
DisclosureSEC source: 0001209191-20-039086 · doc4.xml · nonDerivative · entry 5 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,822 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.40 to $75.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 24, 2020 Filed Jun 26, 2020 20:33 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 26,422 | $12.57 | $332,124.54 |
DisclosureSEC source: 0001209191-20-039086 · doc4.xml · nonDerivative · entry 4 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,422 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 24, 2020 Filed Jun 26, 2020 20:33 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 22,700 | $76.50 | $1,736,574.97 |
DisclosureSEC source: 0001209191-20-039086 · doc4.xml · nonDerivative · entry 3 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.32 to $76.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 24, 2020 Filed Jun 26, 2020 20:33 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 15,966 | $75.93 | $1,212,264.85 |
DisclosureSEC source: 0001209191-20-039086 · doc4.xml · nonDerivative · entry 2 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,700 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.32 to $76.31, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 24, 2020 Filed Jun 26, 2020 20:33 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 38,666 | $5.86 | $226,582.76 |
DisclosureSEC source: 0001209191-20-039086 · doc4.xml · nonDerivative · entry 1 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2020 Filed May 13, 2020 20:38 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $5.86 | $0.00 |
DisclosureSEC source: 0001209191-20-028839 · doc4.xml · derivative · entry 4 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,666 Underlying: Common Shares · 25,000 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The Reporting Person was granted an option to purchase 106,666 shares on March 2, 2016. 43,000 of such options were previously exercised, and the shares underlying those options were sold. 25% of this option became vested and fully exercisable on February 1, 2017, and the remaining 75% of the shares shall vest in 36 equal monthly installments on the first day of each month thereafter. Read SEC document |
| May 11, 2020 Filed May 13, 2020 20:38 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 682 | $61.07 | $41,649.74 |
DisclosureSEC source: 0001209191-20-028839 · doc4.xml · nonDerivative · entry 3 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.025 to $61.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 11, 2020 Filed May 13, 2020 20:38 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 24,318 | $60.38 | $1,468,320.84 |
DisclosureSEC source: 0001209191-20-028839 · doc4.xml · nonDerivative · entry 2 Klein Lawrence Otto · CIK 0001762583 · CBO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,682 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.00 to $60.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.